Cytovale | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights
Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated...
Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Their FDA cleared IntelliSep test analyzes white blood cells to stratify a patientβs risk of sepsis in under 10 minutes, addressing the urgent need for early detection of this lethal condition.
Website
Headquarters
San Francisco, CA
Size
51-200 employees
Industry
Biotechnology Research
Specialities
medical device
ποΈ Cytovale Product and Pricing News β
π Cytovale CEO, Management and Leadership Team β
βοΈ Cytovale Alternatives and Competitors β
πΌ Cytovale Hiring and Layoffs β
π€ Cytovale Developer, Integration and Automation News β
π Cytovale Financials, Fundraising and Valuation News β
ποΈ Cytovale Product and Pricing News
- Cytovale will showcase their IntelliSep sepsis test at CHEST2024, Booth 1252.
π Cytovale CEO, Management and Leadership Team
-
Chief Financial Officer[email protected]
-
Executive Vice President of People[email protected]
-
Executive Vice President Commercial Strategy[email protected]
-
CTO, Cytovale[email protected]
βοΈ Cytovale Alternatives and Competitors
πΌ Cytovale Hiring and Layoffs
- Cytovale is currently seeking a Business Development Executive in the United States.
π€ Cytovale Developer, Integration and Automation News
π Cytovale Financials, Fundraising and Valuation News
- Cytovale's $100M Series D funding was highlighted on the Nasdaq Tower in Times Square.
- Cytovale, co-founded by UCLA's Dino Di Carlo and Henry Tse, has raised $100M for the hospital rollout of its FDA-cleared early sepsis-detection tool IntelliSep.
- Wilson Sonsini, led by Matt Bresnahan, advised Cytovale on IP matters for their $100 million Series D financing.